1. Introduction {#s0005}
===============

Polyamines (putrescine, spermidine and spermine) are critical components of cell growth and division, particularly in rapidly proliferating cells that include cancerous cells and numerous parasites ([@b0065; @b0120]). A number of enzymes in the biosynthesis of polyamines have been validated as suitable drug targets including ornithine decarboxylase (ODC) ([@b0190]) and *S*-adenosyl-[l]{.smallcaps}-methionine decarboxylase (AdoMetDC) ([@b0195]) as the two major enzymatic activities. Protozoan infections resulting in human parasitic diseases such as African sleeping sickness (caused by subspecies of *Trypanosoma brucei*), Chagas disease (*Trypanosoma cruzi*), leishmaniasis (*Leishmania* spp) and malaria (*Plasmodium* spp) are highly reliant on substantial amounts of polyamines for development and proliferation ([@b0115; @b0040]). Of these diseases, malaria has a high disease incidence in most tropical regions of the world, with *Plasmodium falciparum* parasites being the most lethal.

AdoMetDC catalyses a chokepoint reaction to produce decarboxylated *S*-adenosyl-[l]{.smallcaps}-methionine (dcAdoMet) that is exclusively used for polyamine biosynthesis. The irreversible AdoMetDC inhibitor, 5′-{\[(Z)-4-amino-2-butenyl\]methylamino}-5′-deoxyadenosine (MDL73811), is 100-fold more effective than the ODC inhibitor, [dl]{.smallcaps}-α-difluoromethylornithine (DFMO), in curing murine *T. b. brucei* and *T. b. rhodesiense* infections. Treatment of *T. brucei* parasites with MDL73811 causes an intracellular hypermethylated state due to accumulation of *S*-adenosyl-[l]{.smallcaps}-methionine ([@b0050]) in addition to the detrimental depletion of trypanothione (the principal polyamine-dependent thiol in trypanosomes) ([@b0295; @b0280]). AdoMetDC is considered an attractive drug target in *P. falciparum* parasites due to its unique association with ODC in a heterotetrameric bifunctional protein complex, *Pf*AdoMetDC/ODC ([@b0250; @b0040; @b0285]). MDL73811 inhibits *in vitro* intraerythrocytic *P. falciparum* parasite proliferation ([@b0290; @b0070]), however, this does not result in a hypermethylated state but only depletes intracellular polyamine levels, leading to cellular cytostasis ([@b0270; @b0250; @b0040]).

MDL73811, however, is not clinically useful against parasitic infectious due to poor blood brain barrier penetration, a short plasma half-life, poor oral bioavailability and limited metabolic activity ([@b0290; @b0070; @b0030]). Structure-guided design of MDL73811 derivatives, modified on the ribose and purine moieties through addition of halogens and methyl groups, resulted in a series of compounds with improved ADME toxicity profiles. These included improved aqueous solubility, decreased rates of hepatocyte and microsome clearance, minimal CYP inhibition and half the plasma protein binding capacity compared to MDL73811 ([@b0025; @b0030; @b0125]). Methylation of position 8 of the adenine group resulting in 8-methyl-5′-{\[(Z)-4-aminobut-2-enyl\]methylamino}-5′-deoxyadenosine (Genz-644131) displayed an increased inhibitory potency against heterologous *Tb*AdoMetDC. This compound showed improved cellular toxicity against different *T. brucei* parasite strains, with a longer plasma half-life and improved blood brain barrier penetration in *in vivo* mice ([@b0025; @b0030]). Here, the MDL73811 derivatives were assessed for inhibitory activity against heterologous *Pf*AdoMetDC as well as for inhibition of intraerythrocytic *P. falciparum* parasite proliferation *in vitro*.

2. Methods and materials {#s0010}
========================

2.1. MDL73811 and derivatives {#s0015}
-----------------------------

MDL73811 (5′-{\[(Z)-4-amino-2-butenyl\]methylamino}-5′-deoxyadenosine), Genz-644131 (8-methyl-5′-{\[(Z)-4-amino-2-butenyl\]methylamino}-5′-deoxyadenosine), Genz-644043 (2′-fluoro-5′-{\[(Z)-4-amino-2-butenyl\]methylamino}-5′-deoxyadenosine), and Genz-644053 (2-chloro-5′-{\[(Z)-4-amino-2-butenyl\]methylamino}-5′-deoxyadenosine) ([Table 1](#t0005){ref-type="table"}) were synthesised by the Genzyme Corporation (www.genzyme.com, 2013; [@b0125]).

2.2. Recombinant *Pf*AdoMetDC enzyme inhibition assays {#s0020}
------------------------------------------------------

The monofunctional form of *Pf*AdoMetDC (harmonised gene construct) as well as bifunctional *Pf*AdoMetDC/ODC were heterologously expressed in *Escherichia coli* BL21 Star™ (DE3) cells and purified via Strep-tag affinity chromatography as previously described ([@b0035; @b0285]). To determine the enzyme inhibition activity of the MDL73811 derivatives, an isotope-based bioassay that measures the release of radiolabeled CO~2~ ([@b0035; @b0285]) was performed with 5 μg of either monofunctional *Pf*AdoMetDC or bifunctional *Pf*AdoMetDC/ODC in the presence of 1 μM of each derivative. Results were normalised to the specific activity (nmol/min/mg) of an uninhibited control to determine % inhibition.

2.3. Determination of the inhibition constant of Genz-644131 against *Pf*AdoMetDC {#s0025}
---------------------------------------------------------------------------------

The apparent inhibition constant (*K~i~*app) of Genz-644131 was determined with Kitz and Wilson time dependent enzyme kinetics for irreversible inhibitors as described ([@b0130]). Using the isotope-based bioassay described above, residual enzyme activity was measured following pre-incubation (37 °C) at fixed time intervals (2, 4 and 6 min) with varying inhibitor concentrations (0.02, 0.05 and 0.1 μM) and 1 μg of either monofunctional *Pf*AdoMetDC or bifunctional *Pf*AdoMetDC/ODC, each in duplicate. The reciprocal of the slope in the primary graph (*k*~app~) was plotted against the reciprocal of the inhibitor concentrations to yield the secondary plot, from which the *k*~inact~ and the *K~i~*app values were derived.

2.4. Homology modelling and conformational analysis {#s0030}
---------------------------------------------------

*P. falciparum* and *T. brucei* homology models were generated using the human AdoMetDC crystal structure (PDBid [3DZ2](pdb:3DZ2){#ir0005}) as template similar to a previously described model ([@b0275]). Molecular shape-based alignment between MDL73811 derivatives and the homology model was performed with vROCS (v3.1.0 OpenEyeScientific Software, Inc., Santa Fe, NM, USA, www.eyesopen.com, 2010) (Supplemental data; [Fig. S1](#s0095){ref-type="sec"} and [Table S1](#s0095){ref-type="sec"}). Conformational analysis was performed using Conformation Search and the Minimisation module of Discovery Studio 3.0 suite (Accelrys, Inc.). Detailed methods for homology modelling, molecular shape based alignment and conformational analysis are provided in Supplemental data, S1.

2.5. *In vitro* cultivation of intraerythrocytic *P. falciparum* parasites and IC~50~ determination of MDL73811 derivatives {#s0035}
---------------------------------------------------------------------------------------------------------------------------

Intraerythrocytic *P. falciparum* parasites (strain 3D7; chloroquine sensitive) were maintained in *P. falciparum* culture media as described ([@b0265]). Intraerythrocytic parasites were synchronised to a 95% ring stage population with a 5% sorbitol solution. The effect of MDL73811 derivatives on the proliferation of intraerythrocytic *P. falciparum* parasites at 37 °C for 96 h was determined using a SYBR Green I-based fluorescence assay as described ([@b0265]). MDL73811 and Genz-644131 were dissolved in 1xPBS and Genz-644043 and Genz-644053 in DMSO and incubated with ring stage intraerythrocytic *P. falciparum* parasites (1% parasitaemia, 1% haematocrit) at specific concentrations, serially diluted 2-fold in culture medium (final 0.1% (v/v)) non-lethal DMSO concentration ([@b0105]). Sigmoidal dose--response curves were fitted to the data using SigmaPlot 11.0 with non-linear regression yielding the IC~50~ values (concentration at which 50% inhibition of parasite proliferation was observed).

2.6. Determining parasite recovery following Genz-644131 inhibition {#s0040}
-------------------------------------------------------------------

The ability of the products of polyamine metabolism to rescue parasites from the inhibitory effect of Genz-644131 was determined. Ring stage intraerythrocytic *P. falciparum* parasites (1% parasitaemia, 1% haematocrit) were treated with Genz-644131 (2xIC~50~) in the presence of exogenous spermidine trichloride (non-toxic concentration, 250 μM, results not shown) and 500 μM of the polyamine oxidase inhibitor, aminoguanidine ([@b0170]), for 96 h at 37 °C and parasite proliferation determined with a SYBR Green I-based assay ([@b0220; @b0135]).

Subsequently, to determine the ability of ring stage intraerythrocytic *P. falciparum* parasites (1% parasitaemia, 1% haematocrit) to recover after Genz-644131 treatment, the latter was withdrawn following 24 h incubation at 37 °C at 2 × IC~50~, the parasites washed and subsequently resuspended in normal culture media. Samples were removed at 12 h intervals over 96 h and DNA content was determined for the treated, untreated and the Genz-644131 withdrawn parasite populations using a SYBR Green I-based assay.

2.7. Spermidine uptake in intraerythrocytic *P. falciparum* parasites {#s0045}
---------------------------------------------------------------------

Intraerythrocytic *P. falciparum* parasites were purified to ⩾ 95% parasitaemia with magnetic separation ([@b0235; @b0225]). \[^3^H\]spermidine uptake was initiated by combining equal volumes of cell suspension and radiolabelled solution (1 μCi/ml \[^3^H\]spermidine at 5 nm extracellular concentration, PerkinElmer, in 125 mM NaCl, 5 mM KCl, 20 mM glucose, 25 mM HEPES and 1 mM MgCl~2~, pH 7.1). At predetermined time intervals following incubation at 37 °C, the reactions were terminated by dibutyl phthalate sedimentation. A 10 μl sample of the aqueous phase was transferred to a scintillation vial to determine the extracellular concentration of \[^3^H\]spermidine. The remaining cell pellet was lysed with 0.1% (v/v) Triton X-100, the proteins precipitated with 5% w/v trichloroacetic acid and cell debris (including membrane fractions) removed with centrifugation before measuring the radioactivity present in the aqueous supernatant. The rapid initial association of radiolabel with the cells, due to polyamines trapped in the extracellular space as well as adhering to the cell surface was determined and subtracted from the total measured radioactivity (cmp's) to determine the intracellular concentration of polyamines. The data are given as a distribution ratio of intracellular to extracellular spermidine ([@b0210]).

2.8. Comparative IC~50~ determination of Genz-644131 incorporated with Pheriod^®^ technology {#s0050}
--------------------------------------------------------------------------------------------

A micellular formulation of a nanoparticle structure, Pheroid^®^, consisting mainly of 43.8% plant and essential ethylated and PEGylated polyunsaturated fatty acids, was prepared in incomplete RPMI 1640 medium as described ([@b0100; @b0215]). The suspension was subsequently filtered (0.22 μm), diluted 50 × with sterile water and homogenised with Genz-644131 powder to yield an encapsulated suspension with a final compound concentration of 23.75 mM. The encapsulation efficiency of Pheroid^®^ was analysed with confocal laser scanning microscopy ([@b0095]). Subsequently, ring stage intraerythrocytic *P. falciparum* parasites (1% parasitaemia, 1% haematocrit) were treated with Genz-644131 encapsulated Pheroid^®^ at a 20-fold dilution (24 μM initial starting concentration) and incubated for 96 h at 37 °C. Parasite proliferation of cell suspensions treated with Genz-644131 encapsulated into Pheroid^®^ was determined, and normalised against non Genz-644131 encapsulating Pheroid^®^ in order to derive the IC~50~ value using a SYBR Green I-based assay.

2.9. Comparative IC~50~ determination of Genz-644131 with immunoliposomes {#s0055}
-------------------------------------------------------------------------

Immunoliposomes were prepared by the lipid film hydration method ([@b0145]) and covalently functionalised with IgG antibody fragments prepared specifically for intraerythrocytic *P. falciparum* parasites ([@b0240]). For encapsulation of Genz-644131, 1.74 mg of the compound was incorporated into a 1.5 ml immunoliposome suspension to give a final concentration of encapsulated Genz-6644131 at 30 μM (10% encapsulation efficiency). Ring stage intraerythrocytic *P. falciparum* parasites (1% parasitaemia, 1% haematocrit) were treated with Genz-644131 encapsulated immunoliposomes at a 50-fold dilution (0.6 μM starting concentration) and incubated for 96 h at 37 °C. Parasite proliferation of cell suspensions treated with Genz-644131 encapsulated into immunoliposomes was determined as described above.

2.10. Statistical analyses {#s0060}
--------------------------

All data are representative of at least three independent biological experiments (*n* ⩾ 3), each performed in triplicate. Statistical analysis was performed using either paired or unpaired Student's *t*-tests. Data were analysed using GraphPad Prism 5.0 or SigmaPlot 11.0.

3. Results {#s0065}
==========

3.1. Inhibitory effect of MDL73811 derivatives on heterologous monofunctional *Pf*AdoMetDC and bifunctional *Pf*AdoMetDC/ODC {#s0070}
----------------------------------------------------------------------------------------------------------------------------

MDL73811 and Genz-644131 showed the highest percentage inhibition of monofunctional *Pf*AdoMetDC at 98% and 100%, respectively (*n* = 3, *P* \< 0.01, paired Student's *t*-test) ([Fig. 1](#f0005){ref-type="fig"}). The inhibition of the *Pf*AdoMetDC domain of heterologous bifunctional *Pf*AdoMetDC/ODC was similar at 96% and 98%, respectively (*n* = 3, *P* \< 0.01, paired Student's *t*-test) ([Fig. 1](#f0005){ref-type="fig"}). By contrast, Genz-644043 only inhibited monofunctional *Pf*AdoMetDC by 57% (*n* = 3, *P *= 0.14, paired Student's *t*-test) whereas Genz-644053 had no inhibitory effect ([Fig. 1](#f0005){ref-type="fig"}).

The activity of *Pf*AdoMetDC decreased in a concentration dependent manner following pre-incubation with Genz-644131 for both monofunctional and bifunctional forms of the protein ([Fig. 2](#f0010){ref-type="fig"}A and C). A non-significant increase in the *K~i~*app value of 0.36 ± 0.10 μM (*n* = 3, *P *\> 0.05, unpaired Student's *t*-test) was determined for Genz-644131 on monofunctional *Pf*AdoMetDC ([Fig. 2](#f0010){ref-type="fig"}B) compared to 0.22 ± 0.09 μM for MDL73811 (results not shown). However, there was a significant difference in the inhibition of bifunctional *Pf*AdoMetDC/ODC by Genz-644131 (*K~i~*app at 0.18 ± 0.02 μM ([Fig. 2](#f0010){ref-type="fig"}D) compared to MDL73811 (0.53 ± 0.09 μM, results not shown) (*n* = 3, *P *= 0.02, unpaired Student's *t*-test).

The efficiency of inactivation (depicted by the *k*~inact~/*K~i~*app ratio) of MDL73811 compared to Genz-644131 against monofunctional *Pf*AdoMetDC was not significantly different at 1.91 and 1.17 μM^−1^ min^−1^, respectively. However, the inactivation efficiency for Genz-644131 against the *Pf*AdoMetDC domain of bifunctional *Pf*AdoMetDC/ODC is 1.6-fold higher (*k*~inact~/*K~i~*app = 3.50 μM^−1^ min^−1^) compared to MDL73811 (*k*~inact~/*K~i~*app = 2.19 μM^−1^ min^−1^). Moreover, there was a ∼3-fold increase in the inactivation efficiency of Genz-644131 against bifunctional *Pf*AdoMetDC/ODC compared to monofunctional *Pf*AdoMetDC (*k*~inact~/*K~i~*app ratios of 3.50 vs. 1.17 μM^−1^ min^−1^), respectively. Genz-644131 seems to therefore be a more effective inhibitor of *Pf*AdoMetDC compared to MDL73811, with marked preference for the protein when found in its native conformation in bifunctional *Pf*AdoMetDC/ODC.

Due to the observed differences in the inhibition of MDL73811 and its derivatives against *Pf*AdoMetDC, the binding capacity of these compounds to *Pf*AdoMetDC was analysed *in silico*. Previously, it was shown that purine nucleoside AdoMetDC inhibitors adopt unusual *syn* conformations and that modification of these inhibitors does not only affect protein ligand interactions but also alter conformational preferences ([@b0230]) ([Supplemental data S1](#s0095){ref-type="sec"}). MDL73811 has an energy difference of 7.6 kcal/mol between the lowest energy conformation and its bioactive *syn* conformation ([Table 1](#t0005){ref-type="table"}). However, the 8-methyl substitution on the purine rings of MDL73811, yielding Genz-644131, increases the conformational preference for the bioactive *syn* conformation of the latter (energy difference equal to 2.2 kcal/mol, [Table 1](#t0005){ref-type="table"}). By contrast, the energy differences for both the halogen substituted Genz-644043 and Genz-644053 derivatives were higher, with the latter also showing a distorted *N*-(Z)-4-aminobutenyl-*N*-methyl tail conformation due to interference of the chlorine substitution at position 2 of the purine ring ([Supplemental data S1](#s0095){ref-type="sec"}).

The selected binding pose of Genz-644131 ([Fig. 3](#f0015){ref-type="fig"}A) shows similar interactions to other AdoMetDC substrate analogues ([Fig. 3](#f0015){ref-type="fig"}B) ([@b0160]). Moreover, conformational search analysis of the *N*-(Z)-4-aminobutenyl-*N*-methyl tail of Genz-644131 showed that the lowest absolute energy of the Genz-644131 *syn* conformation is reached when the tail assumes the predicted binding conformation (-126.9 kcal/mol) ([Fig. 3](#f0015){ref-type="fig"}C). Notably, the 8-methyl substitution on the purine ring does not show any steric hindrance within the protein active site and therefore would not negatively affect ligand binding.

3.2. Genz-644131 is active against *in vitro* intraerythrocytic *P. falciparum* parasites {#s0075}
-----------------------------------------------------------------------------------------

The IC~50~ of the MDL73811 derivatives was determined on intraerythrocytic *P. falciparum* parasites *in vitro* (96 h incubation at 37 °C)*.* Treatment of intraerythrocytic *P. falciparum* parasites with Genz-644131 resulted in a significant, 2-fold decrease in the IC~50~ compared to MDL73811 (IC~50~ = 0.97 ± 0.06 μM vs. 2.21 ± 0.07 μM , *n* = 5, *P* \< 0.01, unpaired Student's *t*-test). The IC~50~ values of Genz-644043 and Genz-644053 against intraerythrocytic *P. falciparum* parasites were significantly higher (25.6 ± 8.4 and 22.4 ± 7.5 μM; *n* = 4, *P *\> 0.05, unpaired Student's *t*-test) than that of the parent compound, MDL73811.

The ability of exogenous polyamines to rescue the inhibitory effect of Genz-644131 on intraerythrocytic *P. falciparum* parasites was established by determining the IC~50~ of Genz-644131 in the presence and absence of exogenous spermidine (250 μM). No significant change in the IC~50~ value of Genz-644131 in the presence (IC~50~ = 0.94 ± 0.03 μM) or absence (IC~50~ = 0.97 ± 0.06 μM) of spermidine (*n* = 3, *P *= 0.89, paired Student's *t*-test) was observed ([Fig. 4](#f0020){ref-type="fig"}A), indicating that spermidine could not antagonise the inhibitory effect of Genz-644131. However, *P. falciparum* infected erythrocytes are capable of taking up exogenous spermidine, with \[^3^H\]spermidine reaching a distribution ratio of 1.4 ± 0.4 (*n* = 6) following 60 min incubation ([Fig. 4](#f0020){ref-type="fig"}B).

The recovery of intraerythrocytic *P. falciparum* parasites (1% parasitaemia, 1% haematocrit) after limited exposure to Genz-644131 (2× IC~50~) for 24 h was determined after washing out the compound, followed by additional incubation of parasite cultures for a further 96 h before measuring DNA content as an indicator of parasite proliferation. There was a significant increase in DNA levels observed for untreated parasites over the two life-cycles analysed ([Fig. 4](#f0020){ref-type="fig"}C). Genz-644131 treated ring-stage intraerythrocytic *P. falciparum* parasites (2× IC~50~) were able to recover after 24 h of drug pressure and continue to proliferate following drug removal ([Fig. 4](#f0020){ref-type="fig"}C). However, continuous exposure of intraerythrocytic *P. falciparum* parasites to Genz-644131 (2× IC~50~) for 96 h resulted in a stage-specific inhibition of parasite proliferation, with parasites arrested in the trophozoite stage (∼24 h post-invasion) within the first life-cycle ([Fig. 4](#f0020){ref-type="fig"}D).

3.3. Effect of Genz-644131 encapsulated in nanovectors on *in vitro* antiplasmodial activity {#s0080}
--------------------------------------------------------------------------------------------

To improve membrane translocation of Genz-644131 and possibly the *in vitro* activity against intraerythrocytic *P. falciparum* parasites, Genz-644131 was encapsulated into two types of nanovectors, a submicron micellular emulsion formulation, Pheroid^®^ ([@b0100]), and a parasite targeting immunoliposome system ([@b0240]). The compound encapsulated into Pheroid^®^ did not show a significant decrease in the *in vitro* IC~50~ (0.97 ± 0.06 μM compared to 0.67 ± 0.29 μM; *n* = 4, *P *\> 0.05, unpaired Student's *t*-test; [Fig. 5](#f0025){ref-type="fig"}A). By contrast, Genz-644131 encapsulated immunoliposomes showed a significant 32-fold decrease in the *in vitro* IC~50~ compared to non-encapsulated Genz-644131 (0.97 ± 0.06 μM vs. 0.031 ± 0.004 μM; *n* = 3, *P* \< 0.01, unpaired Student's *t*-test) ([Fig. 5](#f0025){ref-type="fig"}B).

4. Discussion {#s0085}
=============

Polyamine biosynthesis enzymes have been the target of various parasitic disease intervention strategies ([@b0040]) as highlighted by the clinical treatment of *T. brucei* infections through DFMO inhibition of ODC activity ([@b0255]). Of the other enzymatic activities associated with polyamine biosynthesis, inhibition of AdoMetDC shows promise as a therapeutic target in *P. falciparum*, with MDL73811 a 1000-fold more potent against intraerythrocytic *P. falciparum* parasites compared to DFMO ([@b0290]). Although MDL73811 is an irreversible inhibitor of AdoMetDC activity, it has poor drug-like characteristics for *Plasmodium* ([@b0290]) and *Trypanosoma* parasites ([@b0030]), which led to the synthesis of pharmacokinetically amenable derivatives. These derivatives of MDL73811 were used here to determine (1) their efficacy in inhibiting the *Pf*AdoMetDC protein and (2) their antiproliferative activity against intraerythrocytic *P. falciparum* parasites *in vitro*.

Several comparisons can be drawn between the treatment of *P. falciparum* and *T. brucei* parasites with the lead derivative, Genz-644131. Firstly, the AdoMetDC protein from both these parasites responds similarly to Genz-644131 treatment. *Pf*AdoMetDC has a near conserved active site compared to AdoMetDC homologues from human and *T. brucei* parasites, despite an overall low sequence identity (21% and 23%, respectively ([@b0275])). As a result, MDL73811 inhibits AdoMetDC from both *P. falciparum* and *T. brucei* parasites at comparable levels and in a similar manner as indicated by their respective micromolar *K~i~*app values ([@b0045; @b0070; @b0285]). However, Genz-644131 potently inhibits monofunctional and bifunctional *Pf*AdoMetDC similarly to *Tb*AdoMetDC ([@b0030]) with *K~i~*app values in the nanomolar range ([@b0030]).

The 1.6-fold decrease in *K~i~*app between MDL73811 and Genz-644131 observed for the bifunctional *Pf*AdoMetDC/ODC is explained by the 8-methyl substitution on the purine ring of Genz-644131, which promotes the preferred bioactive *syn* conformation ([@b0195]). However, Genz-644131 is ∼7-fold less effective in inhibiting monofunctional *Pf*AdoMetDC compared to the *T. brucei* enzyme (*k*~inact~/*K~i~*app ratios of 1.17 μM^−1^ min^−1^ for *Pf*AdoMetDC compared to 7.78 μM^−1^ min^−1^ for *Tb*AdoMetDC ([@b0030])). The association of *Pf*AdoMetDC with ODC in the biologically relevant bifunctional protein *Pf*AdoMetDC/ODC has been shown to result in the modulation of plasmodial AdoMetDC activity ([@b0040; @b0285]). Rate-limiting and equimolar synthesis of putrescine and dcAdoMet by the ODC and AdoMetDC activities is enabled by a decrease in AdoMetDC activity when associated in the bifunctional complex with ODC in comparison to its monofunctional *Pf*AdoMetDC form, respectively ([@b0285]). Here, although comparative inactivation efficiencies are seen for Genz-644131 for the monofunctional and bifunctional proteins, this inhibitor shows a ∼3-fold increase in specificity and rate of inhibition of the AdoMetDC domain of the bifunctional protein. This can be attributed to the lower substrate *K*~m~ of *Pf*AdoMetDC in the bifunctional protein compared to the monofunctional protein, which probably reflects differences between active site conformations of these two proteins and consequently, their binding affinities for Genz-644131 ([@b0285]). Interestingly, the simultaneous inhibition of both activities of the bifunctional *Pf*AdoMetDC/ODC with Genz-644131 and DFMO is additive as was also shown for MDL73811 and DFMO on *in vitro P. falciparum* parasites ([@b0290; @b0250]) ([Supplemental data S2](#s0095){ref-type="sec"}).

In contrast to the marked improvement (\>10-fold) in the *in vitro* antiproliferative efficacy of *T. brucei* parasites treated with Genz-644131 compared to MDL73811 ([@b0030]), Genz-644131 only shows marginal (2-fold) improvement in the *in vitro* IC~50~ against intraerythrocytic *P. falciparum* parasites. The antiproliferative effect observed with Genz-644131 was not plasmodicidal to the parasite, similar to treatment with MDL73811 and DFMO, with parasite proliferation recovering after limited Genz-644131 exposure (24 h at 2× IC~50~). Both MDL73811 and DFMO treatment result in a cytostatic effect since inhibition is negated by the uptake of exogenous polyamines ([@b0020; @b0070]). Co-treatment of parasites with MDL73811 and exogenous spermidine did not abolish the inhibitory effect of MDL73811 on parasite proliferation, and it was previously suggested that intraerythrocytic *P. falciparum* parasites are incapable of spermidine uptake, since exogenously supplied putrescine, but not spermidine, was capable of overcoming biosynthesis inhibition caused by a variety of inhibitors ([@b0020; @b0070]). Likewise, co-treatment of parasites with Genz-644131 and exogenous spermidine also did not abolish the inhibitory effect of Genz-644131 on parasite proliferation. However, recent work clearly indicates that exogenous spermidine is taken up by isolated *P. falciparum* trophozoite-stage parasites ([@b0165]). Once inside the infected erythrocyte unit, the parasite is able to efficiently take up spermidine across the plasma membrane in a concentration dependent manner, mediated by an electrogenic process energised by the parasite's membrane potential ([@b0165]). In addition, here we report that exogenous spermidine is taken up by *P. falciparum* infected erythrocytes. Therefore, the inability of spermidine to abolish Genz-644131 inhibition does not appear to be due to the inability of the parasite to take up spermidine. Genz-644131 shows improved *in vivo* cellular toxicity against different *T. brucei* parasite strains ([@b0025; @b0030]). When this compound was tested in a murine malaria model for *in vivo* antimalarial activity, Genz-644131 significantly (*P* \< 0.001) reduced *P. berghei* parasitaemia by 89% when dosed in the Peters model for 4 days at 100 mg/kg/day. Animals dosed with 20 mg/kg/day showed a 37% (*P *= 0.002) reduction. However, in no case was there sterile cure, as all animals had detectable parasitaemia levels on day 4 ([Supplemental data S3](#s0095){ref-type="sec"}). This may be due to the cytostatic effect described above.

The evidence provided does however not exclude the possibility of off target effects of Genz-644131 on *P. falciparum* parasites including its binding to purine deaminases and polyamine oxidases as observed for MDL73811 ([@b0125]), particularly to *P. falciparum* adenosine deaminases ([@b0205]) and erythrocytic polyamine oxidases ([@b0055]). However, Genz-644131 (at 2× IC~50~) arrested parasite development in a stage-specific manner during the trophozoite stages (18--26 h post invasion), as previously described for MDL73811 ([@b0290]). This corresponds to the requirement of polyamines due to the stage-specific expression of *Pf*AdoMetDC/ODC (18--30 h post-invasion) during the trophozoite stage of the asexual cycle ([@b0250]). The parasite arrested temporal phenotype induced by Genz-644131 therefore corresponds to the expression profile of *Pf*AdoMetDC in the parasite as the target for this compound.

Another explanation for the relatively poor activity of Genz-644131 against intraerythrocytic *P. falciparum* parasites may be due to the poor membrane permeability of the compound itself, as low membrane permeability was previously shown to be the only inferior *in vitro* ADME characteristic of the MDL73811 derivatives ([@b0030]). Additionally, for any compound to access the intraerythrocytic *P. falciparum* parasites, they would need to cross the parasite plasma membrane (PPM), parasitophorous vacuolar membrane (PVM) and erythrocyte membrane ([@b0140]). Extracellular *T. brucei* parasites are surrounded by only a single plasma membrane ([@b0260; @b0175]) and cannot synthesise purines *de novo*, and therefore have to acquire host purines ([@b0110]). Adenosine, of which MDL73811 is a structural analogue, is actively transported into *T. brucei* parasites by the *T. brucei* nucleotide transporter 1 (*Tb*NT1) ([@b0075]) and the *T. brucei* aminopurine transporter (*Tb*AT1 or P~2~). The latter transporter has been confirmed to actively transport MDL73811 ([@b0090; @b0150]), which could explain the low nanomolar *in vitro* IC~50~ values of MDL73811 in these parasites. As in *T. brucei*, *Plasmodium* parasites also do not synthesise purines *de novo* and has to recruit exogenous purines from the host ([@b0080]). In contrast to *T. brucei*, multiple transport mechanisms enable the uptake of purines into intraerythrocytic *P. falciparum* parasites including host purine transporters ([@b0200]) as well as parasite derived transporters, *Pf*NT1 and *Pf*NT4 localised in the PPM ([@b0060; @b0185]). Although the latter are low-affinity transporters ([@b0080]), their ability to transport MDL73811 and derivatives needs further investigation.

The development of novel lipid based nanovectors provides a solution for the challenges facing malaria chemotherapeutics, since it has the potential to mediate sustained, targeted drug release thereby increasing the drug plasma half-life, lowering dosage requirements and reducing drug toxicity ([@b0155]). Additionally, lipid-based nanovectors has been shown to eliminate off-target effects by delivery to specific targeted cells, thereby improving the therapeutic efficacy of the compound ([@b0085]). This makes lipid based nanovector drug delivery systems ideal for treatment of intracellular pathogens ([@b0010; @b0015; @b0155]). Previous encapsulations of chloroquine ([@b0240]) and fosmidomycin ([@b0245]) resulted in a 10- and 7.5-fold decrease in the *in vitro* IC~50~ values of these compounds.

To investigate possible enhancement of the uptake of Genz-644131 into intraerythrocytic *P. falciparum* parasites, the compound was incorporated into two nanovector drug delivery systems: Pheroid^®^ and immunoliposomes ([@b0215; @b0240]). The Pheroid^®^ system is a nanovector carrier developed from a submicron micellular emulsion formulation, typically ranging in size from 80 to 300 nm ([@b0215]). These micellular structures can be manipulated in terms of structure, size and morphology to enhance the solubility properties of intended compounds, by entrapment and delivery of compounds across cellular membranes ([@b0215]). Liposomes are synthetic lipid bilayers of up to 200 nm that have the ability to increase drug bioavailability by encapsulating compounds into the hydrophilic core of the lipid bilayer system. Moreover, the liposomal preparations were orientated with half anti-glycophorin A antibodies, specific for intraerythrocytic *P. falciparum* parasites, enhancing the selectivity of Genz-644131 to the parasite ([@b0240]). Here, the 32-fold decrease observed in the *in vitro* IC~50~ of immunoliposome encapsulated Genz-644131 against intraerythrocytic *P. falciparum* parasites suggests that the uptake of Genz-644131 by itself into intracellular *P. falciparum* parasites is restricted. However, the activity of compounds can be improved by either enhancing the chemical pharmacokinetic properties through medicinal chemistry, or encapsulating the compound into drug delivery systems. Although the Genz-644131 immunoliposome combination has not been tested *in vivo*, other immunoliposomal drug suspensions tested against murine mice infections improved the pharmacokinetic profiles of the drugs tested ([@b0180; @b0005]). Encapsulation of Genz-644131 with immunoliposomes may also reduce non-specific off-target effects and in an sustainable release of the drug to prolong its plasma half-life.

The combination of Genz-644131 with a novel nanovector drug delivery system therefore provides the most promising result obtained thus far with this nanovector delivery system against intraerythrocytic *P. falciparum* parasites *in vitro*, and could be evaluated in novel antimalarial drug development.

Appendix A. Supplementary data {#s0095}
==============================

Supplementary Figure 6Supplementary data 1Supplementary data 2Supplementary data 3

We would like to thank Liezl-Marie Scholtz at the DST/NWU Preclinical Drug Development Platform. This work was supported by the Department of Science and Technology through the South African Malaria Initiative, the University of Pretoria, the South African National Research Foundation and by grant BIO2011-25039 from the Ministerio de Economía y Competitividad, Spain, which included FEDER funds, and 2009SGR-760 from the Generalitat de Catalunya, Spain. All studies were conducted under protocols approved by the IACUC of the Medical Sciences campus, University of Puerto Rico and in accordance with the Guide for the Care and Use of Laboratory Animals (National-Research-Council. 1996. Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

![The inhibitory activities of MDL73811 derivatives against monofunctional *Pf*AdoMetDC (grey) and the *Pf*AdoMetDC domain of bifunctional *Pf*AdoMetDC/ODC (black). MDL73811 and the three derivatives (1 μM) were incubated with either 5 μg monofunctional *Pf*AdoMetDC or bifunctional *Pf*AdoMetDC/ODC for 30 min at 37 °C. Specific activity (nmol/min/mg) of the monofunctional and bifunctional *Pf*AdoMetDC domains were normalised against the uninhibited enzymes. Data are representative of three independent experiments performed in triplicate, ±SEM. ^∗∗^*P* \< 0.01, paired Student's *t*-test. Where not shown, the error bars fall within the symbols.](gr1){#f0005}

![Enzyme kinetics of Genz-644131 against monofunctional and bifunctional *Pf*AdoMetDC. Kitz-Wilson inhibition kinetics was used to determine the *K~i~*app for Genz-644131 against monofunctional (A and B) and bifunctional *Pf*AdoMetDC (C and D). Percentage activity was determined from residual enzyme activity, following pre-incubation with Genz-644131 at 0.02 (circles), 0.05 (squares) or 0.1 μM (triangles) concentrations (\[I\]) at specific time intervals (0--6 min) (*E*~t~). The ln(*E~t~*/*E*~0~) of the activity at a specific inhibitor concentration was plotted against the pre-incubation time points using non-linear regression. The reciprocal of the slopes (1/*k*~app~) of the primary plots (A and C) was plotted against the reciprocal of the specific inhibitor concentrations using non-linear regression (B and D), from which the *k*~inact~ (inverse of the y-intercept) and the *K~i~*app (slope multiplied by *k*~inact~) were derived ([@b0130]). Data are representative of three independent experiments performed in triplicate, ±SEM and all values fell into the 95% confidence interval of the mean. Where not shown, the error bars fall within the symbols.](gr2){#f0010}

![A predicted binding pose for Genz-644131 to *Pf*AdoMetDC highlighting conserved residues with *T. brucei* and human protein equivalents. (A) A homology model of *Pf*AdoMetDC bound with Genz-644131 in the active site. The ribbon representing the β-chain is coloured either bright blue or red indicating conserved and non-conserved residues. Likewise, the α-chain ribbon is coloured in a lighter shade. (B) The interacting residues between *Pf*AdoMetDC and Genz-644131. Green lines represent hydrogen bonds formed between the protein and ligand. (C) Representation of the systematic conformational search of the \[(Z)-4-amino-2-butenyl\] methylamino tail with the lowest energy conformations in yellow. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr3){#f0015}

![Uptake of \[^3^H\]spermidine, with rescue and reversibility of Genz-644131 inhibited intraerythrocytic *P. falciparum* parasites *in vitro*. (A) Initial ring stage intraerythrocytic *P. falciparum* parasites were treated with Genz-644131 (serial dilution) alone (squares) or in the presence of 250 μM spermidine (circles, 0.5 μM aminoguanidine present) for 96 h at 37 °C. Parasite proliferation is expressed as a percentage of untreated parasite proliferation at 100%. Data are representative of *n* ⩾ 3 independent experiments performed in triplicate, ± SEM. (B) Time course for the uptake of \[^3^H\]spermidine (5 nM extracellular concentration) into intraerythrocytic *P. falciparum* parasites (circles) at 37 °C over 60 min averaged from five independent experiments and shown ± SEM. A distribution ratio of 1.4 ± 0.4 was obtained, where a ratio of 1 indicates that the radiolabelled polyamine has equilibrated to levels equal to the extracellular levels. (C) Initial ring stage intraerythrocytic *P. falciparum* parasites were either treated with Genz-644131 (2 × IC~50,~ squares) for 96 h at 37 °C or treated with Genz-644131 (2 × IC~50,~ triangles) for 24 h at 37 °C before replacing the culture media thereby removing the Genz-644131 before incubating the parasites for a further 96 h at 37 °C. Untreated initial ring stage intraerythrocytic *P. falciparum* parasites (circles) incubated at 37 °C for 96 h was included as a positive control for parasite proliferation. Samples were taken every 12 h and DNA content was measured as relative fluorescence units using SYBR Green I-based assay. Data are representative of *n* ⩾ 3 independent experiments performed in triplicate, ±SEM. Where not shown, the error bars fall within the symbol. (D) Morphological monitoring of the stage specificity of parasites treated with Genz-644131 (2 × IC~50~), analysing percentage distribution in each life-cycle stage. Treated parasites indicated that Genz-644131 arrested parasite development during the trophozoite stage compared to untreated parasites.](gr4){#f0020}

![The effect of encapsulation of Genz-644131 in different nanovectors on its *in vitro* anti-plasmodial activity. Parasite proliferation of ring stage intraerythrocytic *P. falciparum* parasites was monitored with a SYBR Green I-based assay over 96 h at 37 °C and IC~50~ determined from dilution series. Dose--response curves for Genz-644131 alone (squares) compared to incorporated into (A) Pheroid^®^ or (B) immunoliposomes (circles). Data are representative in each instance of three independent experiments performed in triplicate or quadruplicate, ±SEM. Where not shown, the error bars fall within the symbols.](gr5){#f0025}

###### 

Conformational search analysis of MDL73811 and its derivatives.

                                                                                                    Lowest overall energy conformation[\#](#tblfn1){ref-type="table-fn"}   Lowest *syn* energy conformation[\#](#tblfn1){ref-type="table-fn"}   Number of conformations generated[\#](#tblfn1){ref-type="table-fn"}   Bioactive *syn* conformational number[⁎](#tblfn2){ref-type="table-fn"}, [\#](#tblfn1){ref-type="table-fn"}
  ---------------------------------------------------------------------------------- -------------- ---------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  MDL73811 5′-{\[(Z)-4-amino-2-butenyl\]methylamino}-5′-deoxyadenosine               ![](fx2.gif)   −131.6                                                                 −124.0                                                               200                                                                   22
  Genz-6441318-methyl-5′-{\[(Z)-4-amino-2-butenyl\]methylamino}-5′-deoxyadenosine    ![](fx3.gif)   −132.9                                                                 −130.7                                                               207                                                                   7
  Genz-6440432′-fluoro-5′-{\[(Z)-4-amino-2-butenyl\]methylamino}-5′-deoxyadenosine   ![](fx4.gif)   −131.0                                                                 −117.8                                                               193                                                                   106
  Genz-6440532-chloro-5′-{\[(Z)-4-amino-2-butenyl\]methylamino}-5′-deoxyadenosine    ![](fx5.gif)   −136.0                                                                 −127.8                                                               209                                                                   64

All energies are given in kcal/mol.

Generated conformations were ranked from the lowest to highest energy i.e. the bioactive *syn* conformation of Genz-644131 was ranked the 7th lowest energy conformation from 207 conformations generated.
